WithdrawnNCT05685225
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
Medication studyAges 18–75United StatesAnxiety
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- North MiamiSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 31, 2025
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Allodynic Therapeutics, Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT05685225
- Official title
Show the full official title
Safety and Efficacy of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Single-Site, Phase 2 Randomized Trial
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
North Miami
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Allodynic Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose and Stage 2: Placebo.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
